Who couldn't use good news? From the New England Journal of Medicine,
Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion–positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128. opens in new tab.)"
We're always proud of our faculty and humbled that they give valuable time educating the general public because they believe we are important in the decision-making process. The study authors include Grace faculty, Dr. Jared Weiss, Dr. Melissa Johnson, Dr. Nathan Pennell and Dr. Karen Reckamp; as well as several others who have contributed to our library of articles and videos.